"F-hiSIEC", a human iPS cell-derived intestinal epithelial cell that is optimal for evaluating drug absorbability, is the result of joint research between Professor Tamhide Matsunaga of Nagoya City University and FUJIFILM Corporation. Released by Fujifilm.It is expected to contribute to the evaluation of drug absorbability and the development of oral preparations.
In oral preparations, the main component drug is taken up mainly by the intestinal epithelial cells of the small intestine.Some are metabolized by intracellular enzymes and some are excreted extracellularly.Drugs and metabolites that remain unexcreted are absorbed into the blood and circulate throughout the body.Therefore, evaluation of drug absorption and metabolism in intestinal epithelial cells is important for predicting efficacy and safety according to dose.Although normal human intestinal epithelial cells derived from living organisms are suitable for the evaluation, stable acquisition of the cells is extremely difficult, and Caco-2 cells derived from human colon cancer are generally used. These cells had low drug metabolism activity, and it was difficult to accurately evaluate drug absorption.
"F-hiSIEC" released by FUJIFILM is a human iPS cell developed by combining the technology for inducing differentiation into intestinal epithelial cells established by Professor Matsunaga and the world-class iPS cell-related technology owned by FUJIFILM. Origin of intestinal epithelial cells.
"F-hiSIEC" exhibits performance equal to or better than that of normal human living body-derived intestinal epithelial cells, and enables highly accurate drug absorption evaluation.Moreover, since it is derived from human iPS cells, it can be mass-produced with stable performance.It can be used as cells with functions similar to those of human organisms at any time, and highly accurate evaluation of drug absorption is possible.Furthermore, it has achieved high versatility that can be used in various cell culture vessels.
"F-hiSIEC", which is a drug discovery support cell that induces differentiation of human iPS cells into intestinal epithelial cells of the small intestine, is expected to greatly contribute to the efficiency of future oral drug development.
